Drug Profile
Neoantigen DNA vaccine - AstraZeneca/Washington University School of Medicine
Latest Information Update: 29 Dec 2023
Price :
$50
*
At a glance
- Originator MedImmune; Washington University School of Medicine
- Developer AstraZeneca; Bristol-Myers Squibb; Washington University School of Medicine
- Class Antigens; Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Small cell lung cancer
- No development reported Prostate cancer; Triple negative breast cancer
Most Recent Events
- 14 Dec 2023 Washington University School of Medicine in collaboration with Medimmune terminates a phase-I trial in Triple-negative-breast-cancer in USA due to insufficient funding and unavailability of drugs and equipment (NCT03199040),
- 25 Jul 2022 Bristol-Myers Squibb and Washington University School of Medicine completes a phase I trial in Prostate cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (IM) (NCT03532217)
- 03 Jun 2022 Safety and immunogenicity data from a phase I trial in prostate cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)